Pa/HDa-212-31 is a first-in-class, orally administered drug developed to treat nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD that can lead to cardiovascular disease, cirrhosis and liver-related mortality.

Between 30%-40% of adults in the US have NAFLD and about 3%-12% percent of adults have NASH. NAFLD is found in 40%-80% of people who have type 2 diabetes and in 30%-90% of people who are obese.  There are no medicines approved to treat NAFLD or NASH.